Androstenone derivative
AssigneeGlaxo Wellcome Inc.
InventorsKenneth William Batchelor, Stephen Vernon Frye, George F. Dorsey, Jr., Robert A. Mook, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
Claims8
A method of treating an androgen responsive or mediate condition in a mammal suffering from said condition comprising administering to said mammal a safe and effective amount of 17.beta.-N-(2,5-bis(Trifluoromethyl)) phenylcarbamoyl-4-aza-5.alpha.-andro st-1-en-3-one or a pharmaceutically acceptable solvate thereof.
A method of treating an androgen responsive or mediated condition in a mammal suffering from said condition comprising administering to said mammal a safe and effective amount of a pharmaceutical formulation comprising a safe and effective amount of 17.beta.-N-(2,5-bis(Trifluoromethyl)) phenylcarbamoyl-4-aza-5.alpha.-androst-1-en-3-one or a pharmaceutically acceptable solvate thereof.
Dependencies are inferred from the claim text.